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Abstract
Colchicine is an effective anti-inflammatory agent used to treat gout, coronary artery disease, 
viral pericarditis, and familial Mediterranean fever. It has been found to act by preventing the 
polymerization of the protein called tubulin, thus inhibiting inflammasome activation, 
proinflammatory chemokines, and cellular adhesion molecules. Accumulating evidence 
suggests that some patients with coronavirus disease 2019 (COVID-19) suffer from “cytokine
storm” syndrome. The ideal anti-inflammatory in this setting would be one that is readily 
available, cheap, orally administered, with a good safety profile, well-tolerated, and that 
prevents or modulates inflammasome activation. The researchers selected colchicine for their 
study. This paper is a review of the literature describing the effects of colchicine, which is a 
drug that is being increasingly used, especially when standard therapy fails. Colchicine was 
shown to reduce inflammatory lung injury and respiratory failure by interfering with 
leukocyte activation and recruitment. In this publication, we try to systematically review the 
current data on new therapeutic options for colchicine. The article focuses on new data from 
clinical trials in COVID-19, rheumatic, cardiovascular, and other treatment such as familial 
Mediterranean fever, chronic urticaria, and PFAPA syndrome (periodic fever, aphthous, 
stomatitis, pharyngitis, and cervical adenitis). We also summarize new reports on the side 
effects, drug interactions, and safety of colchicine.
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Colchicine: Mechanism of action
Colchicine (central illustration) is a strong plant alkaloid with a toxic effect, used in herbal 
medicine, obtained from the seeds of the autumn winter plant (Colchicum autumnale).
Colchicine in doses of 1 mg/kg body weight is fatal, but at therapeutic doses it is 
characterized by pleiotropic effects [1, 2]. Colchicine is commonly used in the treatment of 
gout, familial Mediterranean fever (FMF), Behçet’s disease, pericarditis, coronary artery 
disease (CAD), and other inflammatory diseases [1, 2]. Colchicine has multiple mechanisms 
of action (Fig. 1).
The best known mechanisms of action of colchicine are inhibition of microtubule 
polymerization (at a low dose) or stimulation of microtubule depolymerization (at a higher 
dose) [5, 6]. Microtubules are a key component of the cytoskeleton and are involved in many 
cellular processes such as maintaining cell shape transfer of intracellular substances, secretion
of cytokines and chemokines, cell migration, regulation of ion channels, and cell division [1]. 
Colchicine is an antimitotic agent that blocks cell division during metaphase [5, 6].
In addition to the primary microtubule mechanism of action of colchicine, its anti-
inflammatory and immunomodulatory properties encompass several other pathways. 
Colchicine in small doses reduces the level of E-selectin on vascular endothelial cells, which 
prevents the neutrophils from sticking to its surface. Colchicine in higher doses promotes 
elimination L-selectin from neutrophils, preventing these cells from interacting with the 
vascular endothelium [1]. Moreover, colchicine inhibits the activation of innate immunity, the 
so-called NALP3 inflammasome activation (severe acute respiratory syndrome coronavirus 2 
[SARS-CoV-2] stimulates the NALP3 inflammasome), activation caspase 1, and inhibits 
chemotactic release factor from neutrophils, thereby reducing the subsequent recruitment of 
neutrophils to various tissues [5]. Colchicine inhibits the activation and release of interleukin 
1 (IL-1) and interleukin 8 (IL-8) as well as superoxide from neutrophils [7]. An important 
mechanism of action of colchicine is to stimulate the maturation of dendritic cells, which then
become antigen presenting cells [1]. In addition, colchicine inhibits vascular endothelial 
growth factor (VEGF), which reduces the proliferation of vascular endothelial cells [1]. 
Interestingly, a study in rats showed that colchicine reduced the release of tumor necrosis 
factor alpha (TNF-α) by lipopolysaccharide-induced macrophages [8]. In the mouse brain 
macrophage cell line, colchicine inhibited adenosine triphosphate (ATP)-induced interleukin 
1beta (IL-1β) release by preventing microtubule rearrangement and limiting activation of the 
Ras homolog gene family, member A (RhoA) associate, which includes the protein kinase 
(ROCK) pathway [6]. In the presence of colchicine, murine peritoneal macrophages 
demonstrated lower ATP-induced permeability to ethidium bromide and less formation of 
reactive oxygen species (ROS), nitrogen oxide (NO), and release of IL-1β [8]. All these 
compounds increase the inflammatory process and are responsible for interstitial infiltration 
and lung collapse. Through the various mechanisms described above, colchicine can minimize
such damage [1].
Colchicine in the treatment of rheumatic diseases
Gout
A randomized study by Terkeltaub et al. [9] in 184 patients with acute gout assessed 
the effects of large (4.8 mg total over 6 h; n = 52) and small (1.8 mg total over 1 h; n = 74) 
doses of colchicine or placebo (n = 58) for a pain reduction of ≥ 50% after 24 hours without 
rescue treatment. It was shown that pain relief in the first 24 hours was administered by 23 
patients (31.1%) in the low-dose group (p = 0.027 vs. placebo), 18 (34.6%) patients in the 
high-dose group (p = 0.103 compared to placebo), and 29 (50.0%) patients in the placebo 
group. There was no statistically significant difference in the incidence of adverse events 
between low-dose colchicine and placebo (OR 1.5; 95% CI 0.7–3.2). Thus, it was deduced 
that the use of low doses of colchicine allows for effective prevention of pain attacks during 
gout exacerbation [9].
The safety and efficacy of naproxen and low-dose colchicine in the treatment of gout 
attacks were analyzed in a randomized trial by Roddy et al. [10]. Adults with a gout flare 
recruited from 100 general practices were randomized equally to naproxen 750 mg 
immediately then 250 mg every 8 hours for 7 days or low-dose colchicine 500 mg 3 times per 
day for 4 days. The study included 399 people, 200 of whom were taking naproxen and 199 
were taking colchicine. There was no significant between-group difference in average pain-
change scores over days 1–7 (colchicine vs. naproxen: mean difference –0.18; 95% CI –0.53 
to 0.17; p = 0.32). During days 1–7, diarrhea (45.9% vs. 20.0%; OR 3.31; 95% CI 2.01–5.44) 
and headache (20.5% vs. 10.7%; OR 1.92; 95% CI 1.03–3.55) were more common in the 
colchicine group than in the naproxen group, but constipation was less common (4.8% vs. 
19.3%; OR 0.24; 95% CI 0.11–0.54). Thus, there was no difference in pain intensity over the 
7 days between individuals with a gout flare-up who were randomized to either naproxen or 
low-dose colchicine. Naproxen caused fewer side effects, supporting naproxen as the first-line
treatment of gout flares in primary care with no contraindications [10]. Based on the results of
this study, it can be concluded that naproxen may be a good alternative to colchicine in 
patients with contraindications to its use or in people taking medications that may interact 
with it. Naproxen is mainly excreted unchanged, and to some extent it is metabolized by 
CYP1A2 and CYP2C9 (in contrast to colchicine metabolized by CYP3A4).
Osteoarthritis of the knee
In a randomized study, Aran et al. [11] assessed the effect of colchicine administration 
on the course of osteoarthritis of the knee. The study included 61 postmenopausal patients 
with primary osteoarthritis of the knee, who were randomized into 2 groups receiving 0.5 mg 
of colchicine 2×/day or placebo. As an analgesic, acetaminophen in a dose less than 2 g/day 
was used. It was shown that the use of acetaminophen was significantly lower in the 
colchicine group (879.3 ± 369.7) compared to the placebo group (1620.7 ± 393.1; p = 0.000). 
The rate of improvement at the end of 3 months was significantly greater in the colchicine 
group for both patient global assessment and the physician's overall assessment measures 
compared to the placebo group (11.14 ± 4.06 vs. 3.14 ± 2.18, p = 0.000) and (9.83 ± 3.799 vs. 
3.72 ± 3.35, p = 0.000). Thus, this study demonstrated the effectiveness in reducing pain in 
patients with osteoarthritis of the knee [11]. In a study by Erden et al. [12], involving 60 
patients with osteoarthritis of the knee joint, the impact of adding colchicine to paracetamol 
therapy on the course of the disease and total antioxidant capacity was assessed. Patients were
assigned to receive only paracetamol (3 g/day) or paracetamol (3 g/day) + colchicine (1.5 
g/day) for 6 months. It was shown that the clinical parameters assessed using the WOMAC 
scale (Western Ontario and McMaster Osteoarthritis Index) improved significantly in patients 
using colchicine (p > 0.05). The total antioxidant capacity increased only in the colchicine 
group. In both groups the concentration of malondialdehyde was significantly reduced. The 
activities of enzymes: catalase, superoxide dismutase, and glutathione concentration did not 
change in both groups of patients. Thus, it was found that colchicine reduces the 
concentration of malondialdehyde in the blood and increases the total antioxidant capacity in 
patients with osteoarthritis of the knee. This may indicate that colchicine has a modifying 
effect on the course of knee osteoarthritis [12]. Similar results were obtained by Leung et al. 
[13] in a randomized, placebo-controlled, double-blind clinical trial. The study included 109 
patients with osteoarthritis of the knee, randomized to oral treatment with colchicine 0.5 mg 
twice daily or placebo. It was shown that the intake of colchicine significantly reduced the 
mean serum concentration of high-sensitivity C-reactive protein (hs-CRP; p = 0.008) and C-
terminal telopeptides of type I collagen (p = 0.002). In addition, treatment with colchicine 
tended to reduce serum levels of inflammatory markers such as IL-6, IL-8, TNF-α, CD14, and
IL-18, but these differences were not statistically significant. There was no reduction in 
osteoarthritis of the knee symptoms during the 16-week study period. Thus, colchicine in this 
study reduced inflammation and high bone turnover biomarkers known to be associated with 
the severity and risk of degenerative disease progression but did not reduce symptoms [13].
A systematic review of the literature and a meta-analysis by Restrepo-Escobar et al. 
[14] attempted to evaluate the efficacy and safety of colchicine in the treatment of 
osteoarthritis of the knee (primary or related to the deposition of calcium pyrophosphate 
crystals). The review and meta-analysis included 5 randomized clinical trials involving 223 
patients with osteoarthritis of the knee. Colchicine was shown to reduce pain intensity by at 
least 30% compared to control (OR 9.96; 95% CI 2.29–43.36) and improved patient 
functioning (OR 8.92; 95% CI 2.30–34.65). Thus, colchicine appears to be an effective and 
safe treatment alternative for adult patients with osteoarthritis of the knee, whether primary or 
related to calcium pyrophosphate crystal deposition. Its use reduced pain and improved the 
functioning of patients [14].
Behçet’s disease
The efficacy of colchicine in the treatment of Behçet’s disease was assessed in a 
randomized study by Davatchi et al. [15]. The study included 169 patients with Behçet’s 
disease, who were randomized to take colchicine (1 mg/day) or placebo for 4 months. After 4 
months, they were switched (colchicine to placebo, placebo to colchicine) for another 4 
months. The main result was the overall disease activity index (Iran Behçet’s disease dynamic
activity measure [IBDDAM]). As a secondary result, the individual symptoms of Behçet’s 
disease were severity. It was shown that with placebo, IBDDAM worsened from 3.17 to 3.63 
(p = 0.08). For colchicine, IBDDAM improved from 3.35 to 2.75 (p <0.0001). Oral aphthosis,
genital aphthosis, pseudo-alveolitis, and erythema nodosum were significantly improved with 
colchicine, but not with placebo. The difference between the results for men and women was 
not statistically significant. Thus, colchicine reduced the activity of Behçet’s disease [15]. The
study by Sun et al. [16] assessed the anti-inflammatory efficacy of the combination of 
levamisole and colchicine in 64 patients with the mucocutaneous type of Behçet’s disease. 
The concentration of TNF-α, IL-6, and IL-8 in the serum was measured. Levamisole was 
administered at a dose of 50 mg twice daily for patients with 30–50 kg of body weight, or at a 
dose of 50 mg 3 times daily for patients with 50–80 kg of body weight for 3 consecutive days 
at the beginning of each 2-week interval. Colchicine was administered at a dose of 0.5 mg 
once or twice daily according to the severity of the disease. It has been shown that in 43 
patients with serum TNF-α, IL-6, and IL-8 levels above the upper limit of normal, treatment 
with levamisole and colchicine for 0.5–11.5 months statistically significantly decreased levels
of these proteins (p <0.001). Thus, treatment with levamisole and colchicine may result in a 
significant decrease in the level of IL-6, IL-8, or TNF-α in the serum in patients with the 
mucocutaneous type of Behçet’s disease [16].
Colchicine in the treatment of cardiovascular diseases
Pericarditis, post-pericardiotomy syndrome, and postoperative AF
A meta-analysis of 17 prospective clinical trials conducted by Papageorgiou et al. 
assessed the effect of colchicine on the prevention and treatment of cardiovascular diseases 
(pericarditis, postcoricardiotomy syndrome, and postoperative atrial fibrillation [AF] 
recurrence). The meta-analysis included 2082 patients who received colchicine and 1982 
controls, with a mean follow-up of 12 months. Colchicine administration was shown to 
significantly reduce the risk of recurrent pericarditis/postpericardiotomy syndrome (OR 0.37; 
95% CI 0.29–0.47; p < 0.001). In addition, it was shown that colchicine treatment 
significantly reduced the risk of recurrent AF by as much as 46% in patients after cardiac 
surgery or pulmonary vein isolation (OR 0.54; 95% CI 0.41–0.7; p = 0.001). Thus, colchicine 
has been found to be effective in recurrent pericarditis/postpericardiotomy syndrome and 
recurrent AF after surgery [17]. 
The results of the above meta-analysis are consistent with those previously obtained 
by Imazio et al. [18], who conducted a meta-analysis of 5 randomized clinical trials including 
795 patients with pericarditis with an average follow-up of 13 months. The effectiveness of 
colchicine in the primary and secondary prevention of pericarditis was analyzed. Colchicine 
administration was shown to be associated with a reduced risk of pericarditis during follow-up
(relative risk [RR] 0.40; 95% CI 0.30–0.54; p < 0.001) [18]. Similar results were obtained by 
Lennerz et al. [19] in a meta-analysis of 5 randomized clinical trials. These investigators 
found that treatment with colchicine reduced post-operative AF by 31% compared to placebo 
or usual care (18% vs. 27%, RR 0.69; 95% CI 0.57–0.84; p = 0.0002). The length of hospital 
stay after cardiac surgery decreased by 1.2 days following use of colchicine (95% CI from –
1.89 to –0.44, p = 0.002) [19]. A meta-analysis of 6 randomized clinical trials by Salih et al. 
[20] involving 1257 patients also demonstrated the efficacy of colchicine in reducing the risk 
of post-operative AF (OR 0.52; 95% CI 0.40–0.68; p < 0.001) [20]. An interesting 
randomized, double-blind, placebo-controlled study by Shojaeifard et al. [21] assessed the 
efficacy of colchicine in the prevention of acute pericarditis (through its influence on 
constrictive physiology) after cardiac surgery. Patients (n = 160) were randomized to receive 
colchicine at a dose of 1 mg/day from 48 hours before and 0.5 mg twice/day for 5 days after 
surgery. One week after surgery, the incidence of constrictive physiology was reduced in the 
colchicine group (13% vs. 23%), but the difference was not statistically significant. After 4 
weeks of follow-up, 19 (23%) patients in the placebo group and 9 (11%) in the colchicine 
group had constrictive physiology, while 2 of 11 patients (18.2%) recovered. The difference 
was statistically significant (p = 0.038). There was no new case of constrictive physiology 
between weeks 1 and 4 of observation. Thus, the short-term use of colchicine was 
preventative in reducing constrictive physiology after 1 month of open-heart surgery, but not 
after a week [21].
In conclusion, it should be stated that colchicine is a safe and effective drug in the 
prevention of pericarditis and postoperative AF.
Colchicine, together with acetylsalicylic acid (ASA) and non-steroidal anti-
inflammatory drugs (NSAID), is the drug of first choice in the treatment of acute pericarditis 
and to prevent recurrence as an adjunct to ASA/NSAID therapy (class and level of 
recommendation: IA) [22]. The anti-inflammatory treatment regimen proposed by the 
European Society of Cardiology (ESC) for acute pericarditis (first-line therapy) is as follows:
— ASA at a dose of 750–1000 mg every 8 hours for 1–2 weeks (decrease doses by 250–500 
mg every 1–2 weeks);
— ibuprofen at a dose of 600 mg every 8 hours for 1–2 weeks (decrease doses by 200–400 
mg every 1–2 weeks);
— colchicine at a dose of 0.5 mg once (< 70 kg) or 0.5 mg b.i.d. (≥ 70 kg) for 3 months 
(tapering not mandatory, alternatively 0.5 mg every other day [< 70 kg] or 0.5 mg once [≥ 70 
kg] in the last weeks) [22].
The treatment regimen proposed by the ESC for acute recurrent pericarditis (first-line 
therapy):
— ASA at a dose of 500–1000 mg every 6–8 hours (range 1.5–4 g/day) for weeks-months 
(decrease doses by 250–500 mg every 1–2 weeks);
— ibuprofen at a dose of 600 mg every 8 hours (range 1200–2400 mg) for weeks-months 
(decrease doses by 200–400 mg every 1–2 weeks);
— indomethacin at a dose of 25–50 mg every 8 hours (start at lower end of dosing range and 
titrate upward to avoid headache and dizziness) for weeks-months (decrease doses by 25 mg 
every 1–2 weeks);
— colchicine at a dose of 0.5 mg twice or 0.5 mg daily for patients weighing < 70 kg or 
intolerant of higher doses for at least 6 months (tapering not necessary, alternatively 0.5 mg 
every other day [< 70 kg] or 0, 5 mg once [≥ 70 kg] in the last weeks) [22]. 
It is also worth mentioning that the treatment of pericarditis and its recurrences in 
patients with systemic lupus erythematosus with colchicine in a study by Morel et al. [23], 
involving 10 patients, was effective and safe.
Secondary cardiovascular prevention and in-stent restenosis
The interest in colchicine in the treatment of CAD is justified by its anti-inflammatory 
[24, 25] and anti-atherosclerotic effects [26, 27]. It was found that monthly therapy with 
colchicine at a dose of 0.5 mg/day led to a decrease in the concentration of inflammatory 
markers in the blood in patients with chronic CAD [24]. In a randomized and controlled study
by Martínez et al. [26] involving 40 patients with acute coronary syndrome (ACS) and 10 
patients with stable coronary disease, the effect of colchicine administration on the immune 
profile of the patients was assessed. Subjects were randomized to receive oral colchicine (1 
mg dose followed by 0.5 mg an hour later) or no colchicine 6 to 24 hours prior to cardiac 
catheterization. A rapid and significant reduction in the production of pro-inflammatory 
cytokines in the heart, such as IL-1β, IL-6, and IL-18, was demonstrated [25]. Administration 
of colchicine at a low dose to patients with ACS led to the stabilization of atherosclerotic 
plaque in the coronary vessels [26]. Moreover, colchicine significantly reduces the local 
production of chemotactic factors such as chemokine ligand 2 (CCL2), C-X3-C motif 
chemokine ligand 1 (CX3CL1), and (slightly) chemokine ligand 5 (CCL5) in patients with 
ACS [27].
The efficacy of adding colchicine to therapy in secondary cardiovascular prevention in
patients with CAD was the subject of a meta-analysis of 4 randomized clinical trials 
conducted by Samuel et al. [28[. The meta-analysis included 11,546 patients with stable 
coronary disease or ACS, who were administered colchicine (n = 5774, dose 0.5 mg/day) or 
placebo/no colchicine (n = 5820). It was shown that compared to placebo or no colchicine, 
colchicine was associated with a statistically significant reduction in myocardial infarction 
(MI) (hazard ratio [HR] 0.62; 95% CI 0.36–0.88; p < 0.05), ischaemic stroke (HR 0.38; 95% 
CI 0.13–0.63; p < 0.05) and the urgent need for coronary revascularization (HR 0.56; 95% CI 
0.30–0.82; p < 0.05). However, no statistically significant effect of colchicine administration 
was demonstrated on reduction of the risk of cardiovascular mortality (HR 0.82; 95% CI 
0.46–1.18), deep vein thrombosis, or pulmonary embolism (HR 1.13; 95% CI 0.43–1.84). The
effect of colchicine administration on the risk of AF was at the borderline of statistical 
significance (HR 0.86; 95% CI 0.67–1.04). Subgroup analysis of the relatively consistent 
efficacy of colchicine in reducing the risk of MI, ischemic stroke, and the urgent need for 
coronary revascularization. Thus, in secondary cardiovascular prophylaxis, the addition of a 
low dose of colchicine to standard treatment reduces the incidence of major cardiovascular 
events, except for cardiovascular mortality, compared to standard therapy alone [28].
The randomized, double-blind, placebo-controlled study COLCOT (Colchicine 
Cardiovascular Outcomes Trial) conducted by Tardif et al. [29], involving 4745 patients 
recruited within 30 days of MI, assessed the efficacy of colchicine in secondary 
cardiovascular prevention. Patients were randomized to receive either low-dose colchicine 
(0.5 mg/day; n = 2366) or placebo (n = 2370). A statistically significant 50% reduction in the 
risk of urgent hospitalization for angina leading to coronary revascularization was 
demonstrated (HR 0.50; 95% CI 0.31–0.81) and the risk of stroke (HR 0.26; 95% CI 0.10–
0.70). There was also a reduction in the risk of death from cardiovascular causes (HR 0.84; 
95% CI 0.46–1.52), the risk of sudden cardiac arrest (HR 0.83; 95% CI 0.25–2.73) and the 
risk of recurrent MI (HR 0.91; 95% CI 0.68–1.21) [29]. In further analyses of the studied 
group of patients it was shown that the greatest benefits in terms of secondary cardiovascular 
prevention were achieved by those patients who received colchicine within the first 3 days 
after the onset of MI [30]. In the randomized, double-blind, placebo-controlled study, 
LoDoCo2 (Low-Dose Colchicine-2), conducted by Nidorf et al. [31] and involving 5522 
patients with chronic coronary disease, the effectiveness of colchicine administration on the 
risk of cardiovascular events was analyzed. Patients were administered either 0.5 mg of 
colchicine once daily (n = 2762) or placebo (n = 2760) the corresponding placebo. The 
observation time was 28.6 months. The primary endpoint (cardiovascular death, MI, ischemic 
stroke, or ischemia-driven coronary revascularization) in the colchicine group was reduced by
31% (HR 0.69; 95% CI 0.57–0.83; p < 0.001) [31]. 
The most recent meta-analysis of 12 randomized clinical trials by Bytyçi et al. [32] 
summarized knowledge on the efficacy of colchicine in patients with CAD (colchicine: n = 
6351; placebo: n = 6722). The mean follow-up was 22.5 months. The risk of major adverse 
cardiac events (MACE), all-cause death, cardiovascular death, recurrent myocardial 
infraction, stroke, and hospitalization were analyzed. The results of this meta-analysis are 
shown in Figure 2. The authors of the meta-analysis indicate that colchicine appears to be a 
promising therapeutic option for effective prevention of cardiovascular events. The effect of 
colchicine on cardiovascular and all-cause mortality deserves more research, especially long-
term [32]. 
To sum up, colchicine administered at a dose of 0.5 mg/day shows a beneficial effect 
in the secondary prevention of cardiovascular disease [33]. However, it should be mentioned 
that there is no recommendation on the use of colchicine in the ESC and Canadian 
Cardiovascular Society (CCS) guidelines for ST-segment elevation MI/non-ST segment 
elevation MI (STEMI/NSTEMI), which still limits its use in secondary prevention.
A meta-analysis of 9 randomized clinical trials conducted by Masson et al. [34], 
including 6630 patients at high cardiovascular risk, analyzed the effect of colchicine 
administration on the risk of stroke. In this study, 3359 subjects were allocated to receive 
colchicine while 3271 subjects were allocated to the respective control arms. The incidence of
stroke was lower in the colchicine group compared to the placebo group (OR 33; 95% CI 15–
70). Thus, it was found that colchicine significantly reduces the risk of stroke in patients at 
high cardiovascular risk [34]. In the previously cited meta-analysis by Bytyçi et al. [32] it was
also shown that the use of colchicine reduced the risk of stroke (Fig. 2).
In-stent restenosis is a phenomenon sometimes observed after angioplasty procedures 
involving the relapse of stenosis in the artery being treated. The incidence of restenosis after 
percutaneous coronary intervention (PCI) is approximately 8% at 1-year follow-up. Risk 
factors (p < 0.05) for restenosis after PCI include the following: postoperative hypersensitive 
CRP levels (OR 2.309, 1.579–3.375 mg/L), postoperative homocysteine levels (OR 2.202, 
1.268–3.826 μmol/L), history of diabetes (OR 1.955, 1.272–3.003), coronary bifurcation 
lesions (OR 3.785, 2.246–6.377), and stent length (OR 1.269, 1.179–1.365 mm) [35]. The use
of modern drug-eluting stents (DES) and drug-eluting balloons (DEB) in the treatment of 
CAD significantly reduced the incidence of restenosis (which is one of the major 
complications associated with bare metal stents) [36]. Considering the important role of the 
inflammatory process in the pathogenesis of restenosis [37], it seems that the use of colchicine
should be an effective method of preventing this complication.
In a meta-analysis conducted by Papageorgiou et al. [17] colchicine administration 
was not shown to reduce the risk of in-stent restenosis (OR 0.61; 95% CI 0.24–1.57; p = 
0.31). In a randomized, placebo-controlled study, Deftereos et al. [38] analyzed the effect of 
colchicine administration on the incidence of in-stent restenosis in patients with diabetes and a
contraindication to DES implantation (n = 196). Patients were randomized to receive 
colchicine at a dose of 0.5 mg twice daily or placebo for 6 months. It was shown that the 
frequency of in-stent restenosis was 16% in the colchicine group and 33% in the control group
(OR 0.38; 95% CI 0.18–0.79; p = 0.007). The lumen area loss was 1.6 mm2 (interquartile 
range: 1.0 to 2.9 mm2) in patients treated with colchicine and 2.9 mm2 (interquartile range: 1.4
to 4.8 mm2) in the control group (p = 0.002). The use of colchicine in diabetic patients after 
PCI with a metal stent is associated with less neointimal hyperplasia and a reduced incidence 
of in-stent restenosis [38]. A recently published meta-analysis of 10 studies by Tien et al. [39] 
showed that the use of colchicine significantly reduced the risk of restenosis after PCI (OR 
0.46; 95% CI 0.23–0.92).
Colchicine in the treatment of COVID-19
The results of experimental studies have shown that the NLRP3 inflammasome can be 
activated and triggered by various SARS-CoV-2 proteins, and it may then be involved in the 
development of acute respiratory distress syndrome (ARDS), a complication of COVID-19. 
Colchicine, as an important inhibitor of the NLRP3 inflammasome, may be used in the 
treatment of COVID-19 [8, 40, 41]. In an experimental study involving rats with oleic acid 
ARDS, the efficacy of colchicine in preventing lung damage was investigated. Rats were 
administered colchicine at a dose of 1 mg/kg body weight or placebo for 3 days prior to 
induction of ARDS. Four hours later, tests were performed, and it was shown that colchicine 
reduced the histological area of lung damage by 61%, reduced pulmonary edema, improved 
oxygenation of lung tissue by increasing PaO2/FiO2 from 66 ± 13 mmHg (mean ± SEM) to 
246 ± 45 mmHg, and decreased pCO2 and respiratory acidosis. In addition, colchicine 
decreased pulmonary neutrophil recruitment and activation of circulating leukocytes. The 
researchers concluded that colchicine significantly reduced lung damage in the experimental 
ARDS model [42]. In a clinical trial conducted by Fiorucci et al. [43] involving 30 patients 
with mild to moderate idiopathic pulmonary fibrosis, the effects of prednisone (n = 11; dose 1 
mg/kg bw/day) or prednisone + cyclophosphamide (n = 9; dose 0.5, respectively) were 
assessed. mg/kg bw/day and 100 mg/day) or prednisone + colchicine (n = 10; dose of 0.5 
mg/kg bw/day and 1 mg/day, respectively) for the clinical course of the disease. Clinical 
parameters were assessed before treatment and at 6-month intervals for 18 months. Side 
effects and 3-year survival were also studied. None of the regimens was shown to be able to 
influence the course of idiopathic pulmonary fibrosis. However, treatment with colchicine 
with prednisone resulted in fewer side effects, and the reassessment parameters showed a 
significant reduction in dyspnea (p < 0.01). There were no significant differences in survival 
between the 3 groups [43].
In an interesting clinical study by Scarsi et al. [44], involving 262 patients with 
COVID-19, the effectiveness of colchicine (n = 122) was assessed in comparison with 
standard therapy (n = 140). Standard COVID-19 therapy included hydroxychloroquine and/or 
intravenous dexamethasone and/or lopinavir/ritonavir. Antiviral drugs were discontinued in 
the colchicine 1 mg/day group due to potential drug interactions. It was shown that patients 
with COVID-19 receiving colchicine had a reduced mortality on the 21st day of observation 
compared to those receiving standard therapy (63.6% vs. 84.2%; p = 0.001). The results of 
this promising study indicate that administering colchicine to patients with COVID-19 is 
justified and may have potential benefits [44]. In a prospective, randomized, controlled study 
conducted by Deftereos et al. [45], involving 105 patients with COVID-19, the effect of 
adding colchicine to standard therapy on the concentration of cardiac and inflammatory 
biomarkers and the course of COVID-19 was assessed. The patients were divided into a group
receiving standard therapy (n = 50) and a group additionally receiving colchicine (n = 55) for 
standard therapy. Colchicine was administered according to the following schedule: 1.5 mg 
loading dose followed by 0.5 mg 60 min later and maintenance doses 0.5 mg twice daily 
along with standard treatment for up to 3 weeks. Standard treatments mainly consisted of 
chloroquine, hydroxychloroquine, or azithromycin, as well as ritonavir, lopinavir, or 
tocilizumab. It was shown that patients who received colchicine had a statistically 
significantly longer time to clinical deterioration. There was no reduction in mortality in the 
studied COVID-19 patients. There were no significant differences in the levels of highly 
sensitive cardiac troponin or CRP. Thus, it seems that colchicine may improve the prognosis 
of COVID-19 patients [45]. In a prospective randomized, double-blind clinical trial conducted
by Salehzadeh et al. [46], the effect of colchicine administration on the course of the disease 
(symptom course, hospitalization time, incidence of other diseases) was assessed in 100 
patients with COVID-19. The subjects were randomized to a group receiving 
hydroxychloroquine or a group receiving hydroxychloroquine + colchicine. Colchicine was 
used at a dose of 1 mg/day for 6 days. It was shown that the compared groups differed 
statistically significantly in terms of hospitalization time, amounting to 8.12 days in the 
control group vs. 6.28 days in the study group (p = 0.001). Moreover, in patients with 
COVID-19 receiving colchicine, the incidence of fever was significantly lower than in the 
control group (2% vs. 22%, p = 0.02). Thus, it seems that adding colchicine to COVID-19 
treatment may limit the severity of the disease and the time of length of hospital stay [46].
The randomized, double-blind, placebo-controlled clinical trial COL-CORONA by 
Tardif et al. [47], involving 4159 non-hospitalized patients with COVID-19 (polymerase chain
reaction [PCR] confirmed) at high risk of severe disease assessed the efficacy of colchicine 
versus placebo. Colchicine was administered at a dose of 0.5 mg orally twice daily for the 
first 3 days and then once daily for the next 27 days. Colchicine use was found to reduce 
hospitalizations by 25% (OR 0.75; 95% CI 0.57–0.99), need for mechanical ventilation by 
50% (OR 0.50; 95% CI 0.23–1.07), and the mortality rate by 44% (OR 0.56; 95% CI 0.19–
1.66). In the group of patients receiving colchicine, the most common adverse reaction was 
gastrointestinal complaints (23.9% vs. 14.8%). The results of this very promising study may 
be a breakthrough in the outpatient treatment of COVID-19 patients [47].
The recently published COLORIT study (COLchicine versus Ruxolitinib and 
Secukinumab in Open-label Prospective Randomized Trial in Patients with COVID-19) 
indicated the benefits of the following treatment regimen: 1 mg of colchicine for 1–3 days, 
then 0.5 mg for 2 weeks as an effective anti-inflammatory treatment for COVID-19. This 
treatment turned out to be more effective than the administration of expensive anticytokine 
drugs: ruxolitinib and secukinumab. More aggressive protocols used a loading dose of 1.5 mg 
of colchicine, an additional dose of 0.5 mg an hour later, and then dosing of 2 × 0.5 mg daily 
for 3 weeks [48].
Concerns about the impact of chronic diseases and medications on the risk of SARS-
CoV-2 infection and the severity of COVID-19 prompted Haslak et al. [49] to conduct a study
involving 404 sick children with AIDS. Based on the epidemiological interview and 
retrospective analysis of the medical records of the respondents, it was found that during the 
COVID-19 pandemic, 375 patients were treated with colchicine and 48 with biological drugs. 
Twenty-four patients were admitted to the hospital with suspected SARS-CoV-2 infection, 
and 7 of them were confirmed. All patients recovered and no serious complications were 
found. The researchers conclude that pediatric AIDS patients treated biologically with 
colchicine may not be at increased risk of either SARS-CoV-2 infection or severe COVID-19 
[49].
The results of a meta-analysis of studies assessing the impact of colchicine on the 
prognosis of patients with COVID-19 are presented in Table 1.
Currently, several clinical trials are underway to assess the efficacy and safety of 
colchicine in the treatment of COVID-19 (ClinicalTrials.gov).
Overall, the results of studies and meta-analyses indicate that colchicine may be 
effective in treating patients with COVID-19.
Colchicine in the treatment of other diseases
Familial Mediterranean fever 
The therapeutic efficacy of colchicine was assessed in the double-blind, placebo-
controlled study by Dinarello et al. [56], involving 11 patients with FMF. This study showed 
high effectiveness of colchicine in reducing the number of attacks of the disease (p < 0.001) 
compared to placebo.
Resistance to orally administered colchicine is observed in a proportion of patients 
with FMF. The pathomechanism of this resistance is unknown, but it was found that these 
patients had lower concentrations of colchicine in mononuclear cells [57]. In short-term (12 
weeks) studies of intravenous colchicine administration in patients with FMF refractory to 
oral administration, good efficacy and effectiveness have been demonstrated [58, 59]. The 
study by Grossman et al. [60] evaluated the safety and efficacy of long-term intravenous 
colchicine administration in patients with FMF refractory to this drug administered orally. The
study included 15 patients with frequent attacks of FMF, despite the maximum tolerated dose 
of oral colchicine (2–3 mg/day), who were treated with weekly intravenous injections of 1 mg
of colchicine for at least 12 months. Treatment effectiveness was based on changes in the 
frequency, duration, and severity of FMF attacks. Safety was assessed on the basis of adverse 
events. The mean duration of treatment with intravenous colchicine was 5.16 ± 2.85 years. A 
decrease was observed in the mean monthly indexes of abdominal attacks (from 5.6 ± 3.7 to 
1.9 ± 3.3, p = 0.0009), joint attacks (from 6.5 ± 5.1 to 1, 6 ± 1.6, p = 0.01), and total attacks 
(from 22.3 ± 16.2 to 7.4 ± 5.7, p = 0.002). The incidence of adverse events was low and 
mainly related to the gastrointestinal tract. No serious or serious adverse events have been 
reported. Thus, long-term treatment with intravenous colchicine in patients who do not 
respond to oral colchicine treatment is effective and safe [60].
Overall, administration of oral or intravenous colchicine is effective and safe in 
patients with FMF.
Colchicine is also effective in the treatment of chronic urticaria, as well as PFAPA 
syndrome (periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis) [61, 62].
Safety of colchicine use
Oral preparation of colchicine is well absorbed from the gastrointestinal tract, reaching
the maximum concentration in the blood within 1 hour. 30–50% of the drug is bound to 
plasma proteins, and it penetrates into tissues (leukocytes, kidneys, liver, spleen). Colchicine 
is partially acetylated in the liver and then slowly metabolized in other tissues. It is mainly 
excreted in the feces, and 10–20% in the urine. During the use of the drug, its accumulation in
tissues occurs. Only 10% of the drug is excreted within 24 hours of taking a single dose; 
excretion of the active substance may continue for more than 10 days after the end of 
treatment. The half-life of the drug (T1/2) in people with normal renal function is 4.4 hours, 
and 18.8 hours in people with renal insufficiency [2].   
The safety of colchicine in various diseases was assessed in a meta-analysis of 35 
randomized clinical trials by Stewart et al. [63] published in 2020, including 8659 patients. 
Subjects were assigned to receive colchicine (n = 4225), placebo (n = 3956), or comparator (n
= 411). The most common diseases in which colchicine was administered were gout, liver 
cirrhosis, and acute pericarditis. The percentage of patients taking colchicine with any adverse
event was 21.1% (95% CI 19.9–22.4%), while in the reference groups it was 18.9% (95% CI 
17.7–20.1%). The meta-analysis showed that the overall estimated relative risk for any 
adverse event in patients using colchicine compared to the reference groups was 1.46 (95% CI
1.20–1.77, p < 0.001). The most common adverse events were diarrhea and gastrointestinal 
disorders (Fig. 3). The subgroup analysis showed that patients with liver disease had the 
highest relative risk of any adverse event (RR 5.92; 95% CI 2.08–16.82). However, no 
statistically significant differences in the RR of adverse events were found between patients 
with various diseases who used colchicine. Moreover, no statistical significance in relative 
risk of any adverse events was demonstrated at different times of colchicine intake and at 
different doses (< 50 mg; 50 to < 100 mg; ≥ 100 to 300 mg; and > 600 mg). No adverse event 
was found to be related to the patient’s death [63]. Thus, colchicine increases the incidence of 
diarrhea and gastrointestinal adverse events but does not increase the incidence of increased 
liver enzymes, hepatitis, hepatotoxicity and hepatic abnormalities, dysesthesia in the legs and 
paresthesia, muscles (myalgia, muscle cramps, elevated creatine phosphokinase and muscle 
weakness), infections (urinary tract infection, parotiditis, shingles, upper respiratory tract 
infection, nasopharyngitis and sinus congestion), or hematology (anemia, bone marrow 
toxicity, leukopenia and purple). Colchicine also does not increase mortality [63]. The results 
of this meta-analysis indicate that colchicine is a safe and well-tolerated drug.   
Another clinically important concern is the safety of colchicine use in pregnant 
women. This issue was the subject of a meta-analysis of 4 clinical trials conducted by 
Indraratna et al. [64], covering 2125 pregnant women. The effect of colchicine intake (n = 
550) on the risk of miscarriage and fetal malformation was assessed compared to women who 
did not take colchicine (n = 1575). The indications for the use of colchicine were FMF, 
Behçet’s disease, and others. In the analyzed studies, the daily dose of colchicine was 1–2 mg.
In the group of women receiving colchicine due to FMF, there was no statistically significant 
effect of taking colchicine during pregnancy on the risk of miscarriage, fetal malformation, 
cesarean section, and reduced birth weight (Table 2). Interestingly, the analysis of all women 
taking colchicine (regardless of the indication for its use) showed a statistically significant 
reduction in the risk of miscarriage, an increased risk of premature delivery, a reduction in the
gestational age and a reduction in birth weight (Table 2). Thus, treatment with colchicine did 
not significantly increase the incidence of fetal malformations or abortions during pregnancy. 
The results of this meta-analysis provide clinically significant information that supports the 
conclusion that colchicine treatment should not be discontinued in the case of FMF during 
pregnancy [64].
The safety of colchicine may be limited by the presence of contraindications to its use 
and interactions with other drugs [65, 66]. Colchicine is metabolized by cytochrome P450 
3A4 (CYP3A4) and P-glycoprotein; therefore, the use of drugs that are also substrates for 
these enzymes may result in lethal adverse effects. Hence, it is important to ask patients if 
they are using colchicine before prescribing any other medications. The study by Imai et al. 
[67] assessed the number of prescribed prescriptions for colchicine in patients who were 
taking drugs that could interact with it at the same time. The study included 3302 patients who
regularly take colchicine. Based on the analysis of prescriptions for other drugs issued to these
patients, it was found that 43 (1.3%) of them were taking drugs that were strong inhibitors of 
CYP3A4 or P-glycoprotein (clarithromycin, cyclosporin and itraconazole). Of these 43 
patients, 11 had renal and/or hepatic impairment at baseline. Moreover, it was found that 
patients with Behçet’s disease had the highest risk of interaction with colchicine (OR 4.93; 
95% CI 2.12–11.5; p < 0.001). Among patients with Behçet’s disease receiving colchicine and
the drug interacting with it, 25% had renal and/or hepatic impairment. Significant drug 
interactions with colchicine were found in 1% of patients with gout and Behçet’s disease [67].
Thus, in clinical practice, it is always necessary to determine whether a patient taking 
colchicine has contraindications to its use and to pay attention to other drugs regarding 
whether they interact with colchicine.
In summary, colchicine is well tolerated and safe, also in pregnant women. In clinical 
practice, however, the use of colchicine in patients with contraindications and its combination 
with drugs that may interact with it significantly reduces the safety of this drug.
Conclusions
Colchicine, a drug with a long tradition, is now experiencing its renaissance. It is a 
safe and well-tolerated drug. Colchicine is used in rheumatology, cardiology, and neurology, 
and recently there are more and more data on its effectiveness in the treatment of COVID-19 
patients. Colchicine may become an important drug in the early stages of COVID-19 
treatment.
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Central illustration. Colchicine is obtained hicum autumnale) and is characterized by anti-
inflammatory, immunomodulatory, and antimicrotubular properties. It also reduces uric acid 
levels. Colchicine is used in the treatment of rheumatic diseases, cardiovascular diseases, and 
recently also coronavirus disease 2019 (COVID-19).
Figure 1. Mechanism of action of colchicine with regard to its potential role in the treatment 
of coronavirus disease 2019 (COVID-19) [1–4]; TLR4 — toll-like receptor 4; RIG-I — 
retinoic acid-inducible gene I; NALP3 — NACHT, LRR, and PYD domains-containing 
protein 3; IL-1beta — interleukin 1β; IL-6 — interleukin 6; IL-18 — interleukin 18; IL-1R —
interleukin-1 receptor; TNF-alpha — tumor necrosis factor α; VEGF — vascular endothelial 
growth factor









5778 Reduction from severe COVID-19 risk (OR 0.44; 95% CI
0.31–0.63, p < 0.00001, I2 = 0%) and reduction of 
mortality rate from COVID-19 (OR 0.43; 95% CI 0.32–
0.58; p < 0.00001, I2 = 0%)




8 (morality) 5530 Use of colchicine was associated with lower mortality in 
patients with COVID-19 (OR 0.47; 95% CI 0.31–0.72; p 
= 0.001; I2 = 30.9, p = 0.181)




8 (mortality, risk of
mechanical 
ventilation need)
5259 The use of colchicine reduced the risk of death in patients
with COVID-19 (RR 0.62; 95% CI 0.48–0.81; I2 = 22%).
The use of colchicine did not significantly reduce the risk 
of the need for mechanical ventilation (RR 0.75; 95% CI 
0.45–1.25; I2 = 57%)
Colchicine reduces the risk of death in 
COVID-19 patients and may also 
reduce the need for mechanical 
ventilation in these patients
Chiu et al. [53] 6 (mortality) 5033 All studies (6): Colchicine use reduced the risk of death 
in COVID-19 patients (OR 0.36; 95% CI 0.17–0.76).
Observational studies (3): the use of colchicine reduced 
the risk of death in patients with COVID-19 (OR 0.21; 
95% CI 0.06–0.71).
Placebo-controlled randomized trials (3): Colchicine use 
insignificantly reduced the risk of death in COVID-19 
patients (OR 0.49; 95% CI 0.20–1.24)
Colchicine may reduce the risk of 
mortality in individuals with COVID-19
Vrachatis et al.
[54]
6 (mortality) 881 Use of colchicine reduced the risk of death in patients 
with COVID-19 (OR 0.35; 95% CI 0.24–0.52, I2 = 
0.00%)
Colchicine may reduce the risk of death 
in patients with COVID-19




5901 The use of colchicine has been associated with:
— reduction of the risk of death (RR 0.365; 95% CI 
0.555–0.748)
— reduction of hospitalization time (standard deviation 
difference means: 0.338; 95% CI 0.140–0.537)
The obtained results only confirm the 
validity of the concept that colchicine is
an effective anti-inflammatory drug. 
However, insufficient evidence is 
currently available.
Elshafei et al. 
[55]
9 (mortality) 5525 The use of colchicine was associated with a significantly 
lower mortality compared to the control group (OR 0.35; 
95% CI 0.25–0.48)
Colchicine may reduce mortality in 
COVID-19 patients.
Table 1. Summary of the results of meta-analysis of studies assessing the impact of colchicine administration on prognosis in patients with 
coronavirus disease 2019 (COVID-19).
CI — confidence interval; OR — odds ratio; RR — relative risk
Figure 2. Risk ratios of clinical outcomes with colchicine versus placebo. Based on [32]; RR 
— relative risk; MACE — major adverse cardiac events; CV — cardiovascular; MI — 
myocardial infraction.
28
Figure 3. The incidence and relative risk of adverse events in patients using colchicine 
compared to placebo and comparator drugs. Gastrointestinal included: diarrhea, nausea, 
vomiting, abdominal pain, loss of appetite, gas, constipation, tarry stools, and peptic ulcers; 
muscle included: myalgia, muscle cramps, elevated creatine phosphokinase and muscle 
weakness; infectious included: urinary tract infection, parotiditis, shingles, upper respiratory 
tract infection, nasopharyngitis and sinus congestion; liver included: increased liver enzymes, 
hepatitis, hepatotoxicity, and hepatic abnormalities; sensory included: dysesthesia in the legs 
and paresthesia; hematology included: anemia, bone marrow toxicity, leukopenia, and 
purpura. Based on [63]. 
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Table 2. Safety of colchicine in pregnancy in women with familial Mediterranean fever 
(FMF) and in general pregnancy women. Based on [64]. 
Parameter FMF women exposed to 
colchicine
All women exposed to 
colchicine
Miscarriage OR 0.69 (95% CI 0.43 to 1.11),
p = 0.12




OR 0.59 (95% CI 0.12 to 2.93),
p = 0.52
OR 1.08 (95% CI 0.56 to 2.07),
p = 0.82
Pre-term birth No data OR 2.48 (95% CI 1.65 to 3.71),
p < 0.001
Cesarean section OR 1.61 (95% CI 0.65 to 4.03),
p = 0.31




No data MD −1.00 (95% CI −1.05 to 
−0.95), p < 0.001
Birthweight [g] MD −96.72 (95% CI −218.90 
to 25.46), p = 0.12
MD −209.62 (95% CI −381.58 
to −37.66), p = 0.02s
OR — odds ratio; MD — mean difference
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